Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches
Gilead Sciences is now halfway through its 10-year pledge in the US southern states to tackle HIV through community grants, and looking back while also doubling down on new approaches to the still-growing problem.
Its Commitment to Partnership in Addressing HIV in Southern States (COMPASS) is now aiming for an “equity-driven approach” in its grant-giving and support to organizations.
Southern states today account for half of the deaths and 51% of the new cases of HIV in the US — even though only one-third of the population lives there, Gilead says. However, more concerning is the 30% decrease since 2020 in people receiving treatment for HIV, “many of whom were Black Americans who also shouldered a disproportionate share of consequences of the Covid-19 pandemic,” said Darwin Thompson, Gilead director of public affairs in a roundtable discussion on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.